interventional cardiology,drug-eluting stent
Adjust Font Size: Decrease Increase
The MiStent® SES is a CE Marked drug-eluting stent that has been designed to optimize healing. Read more.
July 22, 2015 — Micell Technologies Announces First Patient Enrolled in Registration Trial of MiStent SES in China
Read more.
May 19, 2015 — EuroPCR Late-Breaking Clinical Trials: MiStent SES® Shows Clinical Superiority over Market-Leader Xience V in Propensity Analysis at One and Three Years Post-Treatment
Read more.
Micell Technologies is bringing together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent. The resulting drug-delivery device is intended to redefine the field of interventional cardiology. Read more.
Micell published in the October 2013 issue of JACC Cardiovascular Interventions. Read more..
Micell published in the Journal of Controlled Release on the enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug. Read more.
Caution: The MiStent SES has received CE marking but is not approved in the USA or any other countries. Any other products described on this website are investigational devices that are not available for sale in any country.
Home | About Us | Therapeutic Focus | Product Pipeline | Technology | News | Terms of Use | Privacy Policy | Site Map
© 2015 Micell Technologies, Inc. All rights reserved.
"Micell", "MiStent", and "MiStent SES" are registered trademarks of Micell Technologies, Inc.